Preclinical Hybrid Imaging Platform

A novel preclinical imaging platform enables researchers to improve their research efforts and drug discovery applications.

Available as a modular or integrated system, the Inveon, developed by Siemens Medical Solutions (Erlangen, Germany), can be utilized in any combination of Siemens' preclinical hybrid imaging systems and sophisticated applications for improved research. The system was recently presented at the Academy of Molecular Imaging (AMI) meeting, held in Orlando, FL,USA, on March 25-29, 2006.
"Siemens preclinical solutions are driving medical research from the laboratory to the clinic,” stated Michael Reitermann, president, Molecular Imaging Division, Siemens Medical Solutions. "Inveon offers limitless solutions and the highest performance and versatility available to address research needs from academic and translational research, to drug discovery and development.”

Molecular medicine combines sophisticated imaging with molecular biomarkers to enable the identification of disease pathways and evaluate the actions of novel therapies. As more disease-specific biomarkers are developed, researchers may be able to increase the speed at which drugs come to market. Inveon can help facilitate basic research as well as the drug development process, allowing researchers to identify specific biologic processes, track the efficacy of compounds, and evaluate the effects of disease progression over time.

The system enables unified control of positron emission tomography (PET), single-photon emission computed tomography (SPECT), and computed tomography (CT) data acquisition, and an extremely high PET resolution and sensitivity. Inveon features advanced multi-pinhole SPECT collimators for improved sensitivity and spatial resolution; new PET and SPECT acquisition and processing technology; and a unique PET transmission method for faster and more accurate attenuation correction.




Related Links:
Siemens Medical Solutions